Gilead, Foresite back biotech developer of COVID-19 pill in latest SPAC deal

A little-known biotech company developing an antiviral pill for COVID-19 is going public through a merger with a blank-check company launched by the venture firm Foresite Capital, a deal that will hand the California-based developer $276 million to advance its drug candidate into clinical testing.